Physiologic Markers of Cardiometabolic Risk in People With Type 1 Diabetes

NCT ID: NCT06105931

Last Updated: 2025-05-04

Basic Information

• Recruitment Status: RECRUITING
• Clinical Phase: PHASE1
• Total Enrollment: 15 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2023-12-13
• Study Completion Date: 2028-06-30

Brief Summary

More than 40% of young adults with type 1 diabetes (T1D) also have overweight or obesity. Each of these diagnoses increase the risk of adverse cardiovascular events. Investigators aim to obtain reference data for individuals with T1D who do not have overweight obesity, to understand how close GLP-1 analogue obesity treatment in those with overweight/obesity brings physiologic markers of cardiometabolic risk to those with BMI in the normal range. Specifically, investigators will describe how drivers of gluconeogenesis and lipemia (specifically measured as visceral fat ratio, insulin resistance, and postprandial lipemia,) that contribute to cardiometabolic risk in T1D change over time.

Detailed Description

Primary Objective

The primary objectives of this physiologic study are to:

1. examine how visceral adipose tissue (VAT), measured as VAT/Subcutaneous Adipose Tissue + VAT changes over 1 year in young adults with T1D and body mass index <25kg/m2.

2. determine how hepatic insulin resistance changes over 1 year in young adults with T1D and body mass index <25kg/m2.

3. determine how the area under the curve of triglycerides after a high fat mixed meal tolerance test changes over 1 year in young adults with T1D and body mass index <25kg/m2.

Secondary Objective

The secondary objective[s] of this study are to determine change in:

Aim 1: Weight and % body fat from baseline to 1 year. Aim 2: Suppression of endogenous glucose production (a measure of insulin resistance), expressed as the change in endogenous glucose rate of appearance (mg/kg/min) at baseline and during the low dose (hepatic) phase, and relationship to VAT/(VAT+SAT) from baseline to 1 year. Glucose rate of appearance, glycerol rate of appearance, glucose oxidation, and fat oxidation will be assessed in all clamp phases baseline to 1 year.

Aim 3: Postprandial rise in other atherogenic lipoproteins baseline to 1 year. The data obtained from this protocol will serve as reference data for a randomized clinical trial of GLP-1 analogue obesity in young adults with T1D and overweight/obesity.

The focus of this registration is the primary objective.

Conditions

type1diabetes; Obesity

Study Design

• Allocation Method: NA
• Intervention Model: SINGLE_GROUP
• Primary Study Purpose: BASIC_SCIENCE
• Blinding Strategy: NONE

Study Groups

Young adults with T1D who have a body mass index <25 kg/m2

Young adults with T1D who have a body mass index \<25 kg/m2 will have: abdominal MRI, hyperinsulinemic-euglycemic clamp wtih stable isotope tracer, DEXA scan and a High Fat Mixed Meal Tolerance Test.

Group Type: EXPERIMENTAL

Hyperinsulinemic-euglycemic clamp

Intervention Type: BIOLOGICAL

Hyperinsulinemic-euglycemic clamp will be used to assess insulin resistance. After IVs are placed, participants will be transitioned to intravenous insulin administration for the baseline portion of the study. Stable Isotope Tracer Infusions will assess rates of glucose, lipid metabolism, and beta-hydroxybutyrate turnover during the last 30 minutes of the baseline equilibration period and again during the last 30 minutes of the stepped IV insulin infusion periods.

High Fat Mixed Meal Tolerance Test

Intervention Type: OTHER

After a 12 hour overnight fast, baseline levels of the lipoproteins will be drawn. The YCCI Bionutrition Service kitchen will prepare the standardized high-fat meal. Participants will administer their bolus insulin per their home regimen for the carbohydrates in the high-fat meal, and then they will consume the meal within a 15-minute timeframe.

Interventions

Hyperinsulinemic-euglycemic clamp

Hyperinsulinemic-euglycemic clamp will be used to assess insulin resistance. After IVs are placed, participants will be transitioned to intravenous insulin administration for the baseline portion of the study. Stable Isotope Tracer Infusions will assess rates of glucose, lipid metabolism, and beta-hydroxybutyrate turnover during the last 30 minutes of the baseline equilibration period and again during the last 30 minutes of the stepped IV insulin infusion periods.

Intervention Type: BIOLOGICAL

High Fat Mixed Meal Tolerance Test

After a 12 hour overnight fast, baseline levels of the lipoproteins will be drawn. The YCCI Bionutrition Service kitchen will prepare the standardized high-fat meal. Participants will administer their bolus insulin per their home regimen for the carbohydrates in the high-fat meal, and then they will consume the meal within a 15-minute timeframe.

Intervention Type: OTHER

Eligibility Criteria

Inclusion Criteria

• Provision of signed and dated informed consent form
• Stated willingness to comply with all study procedures and availability for the duration of the study
• Male or female, aged 18 to ≤30 years
• Diagnosed T1D for at least 12 months and with BMI <25 kg/m2.
• HbA1c ≤10%
• Clinical use of continuous glucose monitoring (CGM)
• Any known laboratory safety parameter consistently outside the below extended laboratory ranges in the past year:

1. Baseline creatinine >1.0mg

2. Hypertriglyceridemia (>400 mg/dl)

3. ALT ≥3.5 times the upper normal limit (UNL)

Exclusion Criteria

• Current use of adjunctive diabetes medication or anti-obesity medication
• Insulin dose <0.5 units/kg/day
• Use of lipid lowering prescription medication other than statins or omega-3 products
• Doesn't meet MRI safety criteria or having claustrophobia
• Known liver disease other than non-alcoholic steatosis or non-alcoholic fatty liver disease
• Known renal impairment
• Pregnancy or lactation, or planning to become pregnant during the study period.
• Anemia or known hematologic condition impacting HbA1c reading, or another medical condition that precludes participation.
• Treatment with another investigational drug within the past 1 month
• Past medical history of or self-reported corn allergy

• Minimum Eligible Age: 18 Years
• Maximum Eligible Age: 30 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

NIH

Sponsor Role: collaborator

Yale University

OTHER

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Michelle Van Name, MD

Role: PRINCIPAL_INVESTIGATOR

Yale University

Locations

Yale Pediatric Diabetes Research

New Haven, Connecticut, United States

Site Status: RECRUITING

Countries

United States

Central Contacts

Rehema Mtawali

Role: CONTACT

rehema.mtawali@yale.edu

(475) 414-4035

Other Identifiers

1R01DK134398-01A1

Identifier Type: NIH

Identifier Source: secondary_id

View Link

2000036125

Identifier Type: -

Identifier Source: org_study_id